Brought to you by 
Daewoong gets Asian rights to Bridge Bio's UC candidate
27 Dec 2019
Executive Summary
Bridge Biotherapeutics Inc. licensed Daewoong Pharmaceutical Co. Ltd. exclusive rights to develop and commercialize its ulcerative colitis candidate BBT401 in China, Japan, and South Korea.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Daewoong gets Asian rights to Bridge Bio's UC candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice